Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2509-4254
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma ; day:11 ; month:10 ; year:2019 ; pages:1-11
PharmacoEconomics - open ; (11.10.2019), 1-11
- Urheber
-
Rifkin, Robert M.
Bell, Jill A.
DasMahapatra, Pronabesh
Hoole, Michael
Lowe, Maria
Curran, Chris
Campbell, Scott
Hou, Peijie
Romanus, Dorothy
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s41669-019-00184-9
- URN
-
urn:nbn:de:101:1-2020022314291453780546
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rifkin, Robert M.
- Bell, Jill A.
- DasMahapatra, Pronabesh
- Hoole, Michael
- Lowe, Maria
- Curran, Chris
- Campbell, Scott
- Hou, Peijie
- Romanus, Dorothy
- SpringerLink (Online service)
Ähnliche Objekte (12)
Muscle and fat composition in patients with newly diagnosed multiple myeloma
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Short overview on the current standard of treatment in newly diagnosed multiple myeloma
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
Muscle and fat composition in patients with newly diagnosed multiple myeloma
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Short overview on the current standard of treatment in newly diagnosed multiple myeloma
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma
Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
Muscle and fat composition in patients with newly diagnosed multiple myeloma
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma
Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma
Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Short overview on the current standard of treatment in newly diagnosed multiple myeloma
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma